A UK SEC declaration for a UK start-up Rockley Photonics has revealed a significant link to Apple that could lead to the introduction of blood sugar monitoring features in the Apple Watch immediately after 2022.
Rockley Photonics is a UK-based company that designs sensors to monitor a person’s blood using infrared light. Sensors are thought to be able to monitor elements that are usually possible with the help of medical or specialized equipment, including monitoring blood sugar and alcohol levels.
The SEC filing was first reported by the United Kingdom TelegraphThe dress is preparing to go public in New York and has revealed details of its financial relationship. According to the document, Apple has been identified as one of its “few big customers”
Rockley claims that the two largest customers of its books represent 100% of the company’s revenue in 2020 and 99.6% in 2019. Although it is unclear whether Apple is the company’s largest or second largest customer , it seems very likely that Apple’s interest in sensors and the improvement of their products, as well as their indication in the declaration, can be equated to the fact that it is a major customer at launch.
The company is said to have an ongoing “supply and development agreement” with the company, which it expects to continue to rely on for most of its revenue. Most of its revenue also comes from engineering fees for the development of future products.
Rockley CEO Andrew Rickman said he expects the technology developed by the company to be in consumer products by 2022, but declined to say whether it will include Apple.
Apple has long been rumored to be working on ways to add glucose monitoring to the Apple Watch, with rumors of the “Apple Watch Series 7” claiming that this feature is on the way. Apple is also working on patent applications for components that could be used to monitor glucose levels through the skin instead of relying on blood draws.